A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age

NCT00534248 Phase 3 COMPLETED Results posted

This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	COMPLETED
Enrolment	22439
Start date	2007-10
Completion	2010-01

Conditions

• Shingles

Interventions

• Zoster Vaccine, Live (Zostavax™)
• Comparator: Placebo

Primary outcomes

• Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group — 2 Years
  Incidence rate of HZ cases was defined as the number of confirmed HZ cases per 1000 person-years of follow-up following vaccination. Vaccine efficacy for HZ was defined as the relative reduction in incidence rate of HZ in the group that received Zostavax™ compared with the group that received placebo based on the intent-to-treat population.